Innocan Pharma paves its way to LPT-CBD CMC key milestones for FDA approval
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million
Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue